共 205 条
[11]
Papadopoulos N(2012)Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis J Clin Oncol. 30 3640-468
[12]
Croll SD(2010)Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials Am J Hypertens. 23 460-930
[13]
Ho L(2013)Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis Br J Clin Pharmacol. 75 919-2974
[14]
Russell M(2013)Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis Int J Cancer. 132 2967-439
[15]
Keunen O(2013)Incidence and risk of hypertension with a novel multi-targeted kinase inhibitor axitinib in cancer patients: a systematic review and meta-analysis Cancer Chemother Pharmacol. 71 431-357
[16]
Johansson M(2013)Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis Br J Clin Pharmacol. 76 348-38
[17]
Oudin A(2010)Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Oncology. 79 27-123
[18]
Sanzey M(2008)Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis Lancet Oncol. 9 117-2285
[19]
Rahim SA(2008)Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab JAMA. 300 2277-1239
[20]
Fack F(2007)Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis J Natl Cancer Inst. 99 1232-11